SAN DIEGO--(BUSINESS WIRE)--Zogenix, Inc., a privately held neuroscience-focused specialty pharmaceutical company, announced today it has received $3.5 million of a $10 million loan facility with GE Healthcare Financial Services. Zogenix will use the loan to finance the launch of its first product, sumatriptan Intraject®, for the acute treatment of migraines.
